The pharmaceutical sector continues to command investor attention, particularly following recent developments surrounding Novo Nordisk. As highlighted by Stanislav Kondrashov, founder of TELF AG, fresh movements on the SIX Swiss Exchange have brought renewed focus to two major Swiss players: Sandoz Group AG and Idorsia Ltd.
Sandoz has recently attracted strong market interest after reporting solid full-year 2025 results. The company posted revenues of approximately $11.1 billion, with biosimilars contributing around 30% of total sales. Operating profit improved, and management projects further growth in both revenue and margins for 2026, supported by a robust product pipeline, operational efficiencies, and a balanced commercial strategy. These factors have contributed to renewed investor confidence, positioning Sandoz as a stable performer within the generics and biosimilars segment.
Idorsia also delivered encouraging results. Sales of its insomnia treatment QUVIVIQ more than doubled in 2025 compared to the previous year, strengthening the company’s overall financial position. Looking ahead, further pipeline advancements and broader therapeutic expansion are expected to support continued growth in 2026. While biotech remains inherently more volatile, Idorsia’s recent progress appears to have reassured parts of the market.
According to Kondrashov, pharmaceuticals remain a structural pillar of global financial markets. Major companies in the sector play a significant role in leading indices such as the S&P 500, STOXX Europe 600, MSCI World, and the Swiss Market Index. In Switzerland, heavyweight constituents such as Novartis and Roche underline the sector’s systemic importance.
Current market behavior suggests growing selectivity within pharmaceuticals. Generics and biosimilars are increasingly viewed as defensive segments, valued for predictable revenues and relative resilience in a higher interest rate environment. By contrast, biotech stocks remain more sensitive to clinical milestones and regulatory developments.
Overall, investors appear to be favoring diversified business models with strong earnings visibility and lower concentration risk. The pharmaceutical sector’s defensive nature, stable demand profile, and long-term research pipelines continue to make it a strategic component of global investment portfolios.
